Akari Therapeutics to Present at Biotech Showcase(TM) 2023
NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle more...
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol
Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol PR Newswire Histological improvement in fibrosis (≥1 stage) was demonstrated in 39% of subjects according more...
Immutep Achieves 50% Enrollment Milestone in Randomised Phase IIb TACTI-003 Trial for First Line Head & Neck Cancer
SYDNEY, AUSTRALIA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces that it more...
New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — XOMA Corporation (NASDAQ: XOMA), the Biotech Royalty Aggregator, announced today more...
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
Topline data expected mid-2023 Potential Biologics License Application (BLA) submission end of 2023 HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) — Aravive, Inc. (Nasdaq: ARAV, the “Company”), a late clinical-stage oncology company developing targeted therapeutics to more...
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer
BioLineRx Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer PR Newswire Experienced Drug Developer Brings Over 15 Years of Clinical Development Industry Knowledge across Multiple Therapeutic Areas and Modalities TEL AVIV, Israel , Jan. 4, more...
EyePoint Pharmaceuticals Promotes Jay S. Duker, M.D. to President and Chief Operating Officer
Dr. Duker has served as EyePoint’s Chief Operating Officer since November 2021 WATERTOWN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) — EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to more...
Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes
Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced Technologies & Treatments for Diabetes Genprex Announces Selection of Preclinical Data for Oral Presentation at 16th International Conference on Advanced more...
NanoViricides, Inc. to Present at the Biotech Showcase(TM) 2023 Conference in San Fransisco on January 9th at 10:30am PT
SHELTON, CT / ACCESSWIRE / January 4, 2023 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), announces that the Company’s President, Dr. Anil Diwan, will be presenting a talk in person at the Biotech Showcase™ 2023 more...
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Vintage Wine, Eiger, Unisys, and Rent and Encourages Investors to Contact the Firm
NEW YORK, Jan. 03, 2023 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Vintage Wine more...